Utilization of buprenorphine and methadone among opioid users who inject drugs

References

• Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374:154–163.
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Behavioral Health Trends in the United States: Results From the 2014 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015.
   Google Scholar
• Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64:1378–1382.
   PubMed Web of Science ®Google Scholar
• Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733–1745.
   PubMed Web of Science ®Google Scholar
• Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571–583.
   PubMed Web of Science ®Google Scholar
• Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone—Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:443–444.
   PubMed Web of Science ®Google Scholar
• Suryaprasad AG, White JZ, Xu F, et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Clin Infect Dis. 2014;59:1411–1419.
   PubMed Web of Science ®Google Scholar
• Fullerton CA, Kim M, Thomas CP, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65:146–157.
   PubMed Web of Science ®Google Scholar
• Saxon AJ, Hser YI, Woody G, Ling W. Medication-assisted treatment for opioid addiction: methadone and buprenorphine. J Food Drug Anal. 2013;21:S69–S72.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
   PubMed Web of Science ®Google Scholar
• Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction. 2005;100:150–158.
   PubMed Web of Science ®Google Scholar
• Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008;(2):CD004145.
   PubMed Web of Science ®Google Scholar
• MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.
   PubMed Web of Science ®Google Scholar
• Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174:1974–1981.
   PubMed Web of Science ®Google Scholar
• Nolan S, Dias Lima V, Fairbairn N, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction. 2014;109:2053–2059.
   PubMed Web of Science ®Google Scholar
• White B, Dore GJ, Lloyd AR, Rawlinson WD, Maher L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. Med J Aust. 2014;201:326–329.
   PubMed Web of Science ®Google Scholar
• Nosyk B, Bray JW, Wittenberg E, et al. Short term health-related quality of life improvement during opioid agonist treatment. Drug Alcohol Depend. 2015;157:121–128.
   PubMed Web of Science ®Google Scholar
• Mitchell SG, Gryczynski J, Schwartz RP, et al. Changes in quality of life following buprenorphine treatment: relationship with treatment retention and illicit opioid use. J Psychoactive Drugs. 2015;47:149–157.
   PubMed Web of Science ®Google Scholar
• Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13:374–381.
   PubMed Web of Science ®Google Scholar
• Heckathorn DD. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44:174–199.
   Web of Science ®Google Scholar
• Saloner B, Karthikeyan S. Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004–2013. JAMA. 2015;314:1515–1517.
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS) 2004–2014: National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016.
   Google Scholar
• Oliva EM, Harris AH, Trafton JA, Gordon AJ. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors. Drug Alcohol Depend. 2012;122:241–246.
   PubMed Web of Science ®Google Scholar
• Greene P. Outpatient drug utilization trends for buprenorphine years 2002–2009. http://buprenorphine.samhsa.gov/bwns/2010_presentations_pdf/09_Greene_508.pdf. Published 2010. Accessed March 24, 2014. ( Archived by WebCite® at http://www.webcitation.org/6OJVKGwyg. Accessed March 24, 2014.)
   Google Scholar
• Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
   Google Scholar
• Korthuis PT, Gregg J, Rogers WE, McCarty D, Nicolaidis C, Boverman J. Patients' reasons for choosing office-based buprenorphine: preference for patient-centered care. J Addict Med. 2010;4:204–210.
   PubMed Web of Science ®Google Scholar
• Gryczynski J, Jaffe JH, Schwartz RP, et al. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addict. 2013;22:285–291.
   PubMed Web of Science ®Google Scholar
• Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39:340–352.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174:1947–1954.
   PubMed Web of Science ®Google Scholar
• Hser YI, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109:79–87.
   PubMed Web of Science ®Google Scholar
• Frimpong JA, D'Aunno T, Jiang L. Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study. Am J Public Health. 2014;104:e75–e82.
   PubMed Web of Science ®Google Scholar
• Hagan H, Pouget ER, Williams IT, et al. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis. 2010;201:378–385.
   PubMed Web of Science ®Google Scholar
• Amon JJ, Garfein RS, Ahdieh-Grant L, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994–2004. Clin Infect Dis. 2008;46:1852–1858.
   PubMed Web of Science ®Google Scholar
• Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(RR-4):1–32.
   PubMedGoogle Scholar